Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00BMF
|
|||
| Former ID |
DCL000571
|
|||
| Drug Name |
MK-4827
|
|||
| Synonyms |
1038915-60-4; (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide; UNII-HMC2H89N35; HMC2H89N35; CHEMBL1094636; 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide; MK4827; MK 4827; Niraparib [USAN:INN]; 2-{4-[(3S)-piperidin-3-yl]phenyl}indazole-7-carboxamide; 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide; MK 4827 (Base); Niraparib (USAN); Zejula (TN); MK-4827(Niraparib); SCHEMBL1421875; GTPL8275; CTK8B9123; EX-A290; DTXSID50146129; MolPort-023-219-142; ZINC43206370; BDBM50316226
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 3 | [1] | |
| Breast cancer [ICD-11: 2C60-2C65] | Phase 2 | [2] | ||
| Ewing sarcoma [ICD-11: 2B52; ICD-9: 170] | Phase 1 | [2] | ||
| Company |
Merck
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H20N4O
|
|||
| Canonical SMILES |
C1CC(CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)N
|
|||
| InChI |
1S/C19H20N4O/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24)/t14-/m1/s1
|
|||
| InChIKey |
PCHKPVIQAHNQLW-CQSZACIVSA-N
|
|||
| CAS Number |
CAS 1038915-60-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
56256045, 57487185, 103749792, 104150587, 135265184, 135626858, 136340151, 136349580, 136367711, 136946461, 137232464, 138192109, 144116229, 152258260, 160647096, 160829563, 162038124, 162113109, 163094037, 163394941, 163843781, 174007122, 186007055, 189561499, 198976487, 202829003, 204430248, 223617456, 227634434, 247056359, 249752894, 252080192, 252166487, 252227886, 252300335, 252462459
|
|||
| ADReCS Drug ID | BADD_D02486 | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Poly [ADP-ribose] polymerase (PARP) | Target Info | Modulator | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03602859) A Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (FIRST). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.